Cyclodialysis procedure with scleral reinforcement lowers IOP in open-angle glaucoma

Key takeaways:

• Cyclodialysis with scleral allograft reinforcement lowered IOP in patients with glaucoma.
• The treatment also displayed a positive safety profile.

A bio-interventional cyclodialysis procedure with allograft scleral reinforcement helped lower IOP in patients with glaucoma through uveoscleral outflow enhancement, according to a study.

In the study published in Clinical Ophthalmology, Robert N. Weinreb, MD, and colleagues evaluated the safety and efficacy of cyclodialysis with scleral reinforcement in patients with open-angle glaucoma who underwent cataract surgery. CycloPen (Iantrek), a microinterventional system for cyclodialysis, and AlloFlo (Iantrek), a bio-interventional enhancement for uveo-scleral outflow, were utilized.

The analysis included 1 year outcomes from 117 eyes enrolled in the CREST Real-World Evidence interventional study. At baseline, mean medicated IOP was 20.2 ± 6.0 mm Hg, and patients used 1.4 ± 1.3 IOP-lowering medications.

At 12 months after surgery, the mean IOP was 13.9 ± 3.9 mm Hg, and the mean number IOP-lowering medications was 0.8 ± 0.9, according to the study. The researchers also found that 81.9% of patients achieved a medicated IOP of 18 mm Hg or lower while on the same or fewer medications.

The researchers also found that the procedure demonstrated a favorable safety profile, and there was a low rate of postoperative complications. Additionally, there were no reports of vision-threatening adverse events, and secondary glaucoma surgery was needed in 3.2% of patients.

“With this study, we demonstrate that bio-interventional enhancement of the uveoscleral outflow pathway has significant IOP-lowering effect similar to what we have seen with pharmacological treatments such as [prostaglandin analogs],” Weinreb told Healio | OSN in an email.

Published by:

Sources/Disclosures

Collapse

Disclosures:
Weinreb reports consulting for Iantrek. Please see the full study for all other authors’ relevant financial disclosures.

Read more about

This post was originally published on this site